Riboflavin, Retbindin, and Riboflavin Transporters in the Retina.

Xue Zhao, Muna I Naash, Muayyad R Al-Ubaidi

Abstract readReview

In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xue ZhaoDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.

Muna I NaashDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA. mnaash@central.uh.edu.ORCID https://orcid.org/0000-0002-6534-5144

Muayyad R Al-UbaidiDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA. malubaid@central.uh.edu.ORCID https://orcid.org/0000-0002-4914-350X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The retina is the most metabolically active tissue in the body. It harbors high levels of flavins due to their involvement as enzymatic co-factors in energy production. Flavins are delivered to the body via specific transporters, the ablation of which leads to riboflavin transporter deficiency (RTD) and ariboflavinosis in humans. RTD leads to embryonic lethality in mice, and in humans, it has detrimental effects on the nervous system, causing neurologic abnormalities. However, the reports on the effects of RTD on retinal homeostasis are limited despite the fact that the retina maintains high levels of riboflavin and its derivatives. We have identified retbindin (Rtbdn) as a retina-specific riboflavin-binding protein, ablation of which leads to reduced flavin levels associated with retinal degeneration in mice. To focus attention on the role of flavins in retinal homeostasis, herein, we discuss the specific functions of flavins and Rtbdn and their protective roles in maintaining retinal health.

Indexed as

Eye ProteinsMembrane Transport ProteinsRetinaRetinal DegenerationRiboflavinAnimalsHomeostasisHumansMiceEye ProteinsMembrane Transport ProteinsRiboflavinriboflavin-binding proteinRTBDN protein, mouseAriboflavinosisRetbindinRiboflavinRiboflavin transporterRiboflavin transporter deficiency

Identifiers

PMID39930240

DOI10.3389/fphar.2022.919667

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.